220 related articles for article (PubMed ID: 32298334)
1. SMOOT libraries and phage-induced directed evolution of Cas9 to engineer reduced off-target activity.
Cerchione D; Loveluck K; Tillotson EL; Harbinski F; DaSilva J; Kelley CP; Keston-Smith E; Fernandez CA; Myer VE; Jayaram H; Steinberg BE
PLoS One; 2020; 15(4):e0231716. PubMed ID: 32298334
[TBL] [Abstract][Full Text] [Related]
2. Engineered dual selection for directed evolution of SpCas9 PAM specificity.
Goldberg GW; Spencer JM; Giganti DO; Camellato BR; Agmon N; Ichikawa DM; Boeke JD; Noyes MB
Nat Commun; 2021 Jan; 12(1):349. PubMed ID: 33441553
[TBL] [Abstract][Full Text] [Related]
3.
Acharya S; Mishra A; Paul D; Ansari AH; Azhar M; Kumar M; Rauthan R; Sharma N; Aich M; Sinha D; Sharma S; Jain S; Ray A; Jain S; Ramalingam S; Maiti S; Chakraborty D
Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20959-20968. PubMed ID: 31570623
[TBL] [Abstract][Full Text] [Related]
4. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.
Hu JH; Miller SM; Geurts MH; Tang W; Chen L; Sun N; Zeina CM; Gao X; Rees HA; Lin Z; Liu DR
Nature; 2018 Apr; 556(7699):57-63. PubMed ID: 29512652
[TBL] [Abstract][Full Text] [Related]
5. Continuous evolution of SpCas9 variants compatible with non-G PAMs.
Miller SM; Wang T; Randolph PB; Arbab M; Shen MW; Huang TP; Matuszek Z; Newby GA; Rees HA; Liu DR
Nat Biotechnol; 2020 Apr; 38(4):471-481. PubMed ID: 32042170
[TBL] [Abstract][Full Text] [Related]
6. Systematic in vitro specificity profiling reveals nicking defects in natural and engineered CRISPR-Cas9 variants.
Murugan K; Suresh SK; Seetharam AS; Severin AJ; Sashital DG
Nucleic Acids Res; 2021 Apr; 49(7):4037-4053. PubMed ID: 33744974
[TBL] [Abstract][Full Text] [Related]
7. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy.
Chen JS; Dagdas YS; Kleinstiver BP; Welch MM; Sousa AA; Harrington LB; Sternberg SH; Joung JK; Yildiz A; Doudna JA
Nature; 2017 Oct; 550(7676):407-410. PubMed ID: 28931002
[TBL] [Abstract][Full Text] [Related]
8. A highly specific SpCas9 variant is identified by in vivo screening in yeast.
Casini A; Olivieri M; Petris G; Montagna C; Reginato G; Maule G; Lorenzin F; Prandi D; Romanel A; Demichelis F; Inga A; Cereseto A
Nat Biotechnol; 2018 Mar; 36(3):265-271. PubMed ID: 29431739
[TBL] [Abstract][Full Text] [Related]
9. Engineered CRISPR/Cas9 enzymes improve discrimination by slowing DNA cleavage to allow release of off-target DNA.
Liu MS; Gong S; Yu HH; Jung K; Johnson KA; Taylor DW
Nat Commun; 2020 Jul; 11(1):3576. PubMed ID: 32681021
[TBL] [Abstract][Full Text] [Related]
10. [The Development of SpCas9 Variants with High Specificity and Efficiency Based on the HH Theory].
Wang GH; Wang CM; Wu XJ; Chu T; Huang DW; Li J
Mol Biol (Mosk); 2024; 58(1):157-159. PubMed ID: 38943587
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial mutagenesis en masse optimizes the genome editing activities of SpCas9.
Choi GCG; Zhou P; Yuen CTL; Chan BKC; Xu F; Bao S; Chu HY; Thean D; Tan K; Wong KH; Zheng Z; Wong ASL
Nat Methods; 2019 Aug; 16(8):722-730. PubMed ID: 31308554
[TBL] [Abstract][Full Text] [Related]
12. Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
Kleinstiver BP; Prew MS; Tsai SQ; Topkar VV; Nguyen NT; Zheng Z; Gonzales AP; Li Z; Peterson RT; Yeh JR; Aryee MJ; Joung JK
Nature; 2015 Jul; 523(7561):481-5. PubMed ID: 26098369
[TBL] [Abstract][Full Text] [Related]
13. A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9.
Maji B; Gangopadhyay SA; Lee M; Shi M; Wu P; Heler R; Mok B; Lim D; Siriwardena SU; Paul B; Dančík V; Vetere A; Mesleh MF; Marraffini LA; Liu DR; Clemons PA; Wagner BK; Choudhary A
Cell; 2019 May; 177(4):1067-1079.e19. PubMed ID: 31051099
[TBL] [Abstract][Full Text] [Related]
14. Generation of genetically modified mice using SpCas9-NG engineered nuclease.
Fujii W; Ito H; Kanke T; Ikeda A; Sugiura K; Naito K
Sci Rep; 2019 Sep; 9(1):12878. PubMed ID: 31501500
[TBL] [Abstract][Full Text] [Related]
15. Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells.
Donohoue PD; Pacesa M; Lau E; Vidal B; Irby MJ; Nyer DB; Rotstein T; Banh L; Toh MS; Gibson J; Kohrs B; Baek K; Owen ALG; Slorach EM; van Overbeek M; Fuller CK; May AP; Jinek M; Cameron P
Mol Cell; 2021 Sep; 81(17):3637-3649.e5. PubMed ID: 34478654
[TBL] [Abstract][Full Text] [Related]
16. In-depth assessment of the PAM compatibility and editing activities of Cas9 variants.
Zhang W; Yin J; Zhang-Ding Z; Xin C; Liu M; Wang Y; Ai C; Hu J
Nucleic Acids Res; 2021 Sep; 49(15):8785-8795. PubMed ID: 34133740
[TBL] [Abstract][Full Text] [Related]
17. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants.
Walton RT; Christie KA; Whittaker MN; Kleinstiver BP
Science; 2020 Apr; 368(6488):290-296. PubMed ID: 32217751
[TBL] [Abstract][Full Text] [Related]
18. Catalytically Enhanced Cas9 through Directed Protein Evolution.
Hand TH; Roth MO; Smith CL; Shiel E; Klein KN; Gilbert DM; Li H
CRISPR J; 2021 Apr; 4(2):223-232. PubMed ID: 33876948
[TBL] [Abstract][Full Text] [Related]
19. Allosteric inhibition of CRISPR-Cas9 by bacteriophage-derived peptides.
Cui YR; Wang SJ; Chen J; Li J; Chen W; Wang S; Meng B; Zhu W; Zhang Z; Yang B; Jiang B; Yang G; Ma P; Liu J
Genome Biol; 2020 Feb; 21(1):51. PubMed ID: 32102684
[TBL] [Abstract][Full Text] [Related]
20. Phosphate Lock Residues of Acidothermus cellulolyticus Cas9 Are Critical to Its Substrate Specificity.
Hand TH; Das A; Roth MO; Smith CL; Jean-Baptiste UL; Li H
ACS Synth Biol; 2018 Dec; 7(12):2908-2917. PubMed ID: 30458109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
